CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma

被引:26
作者
Wang, Xian-Song [1 ]
Sheng, Zhen [1 ]
Ruan, You-Bing [1 ]
Guang, Yang [1 ]
Yang, Mu-Lan [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathol, Wuhan 430030, Hubei Province, Peoples R China
关键词
CpG-oligodeoxynucleotides; Hepatoma; 22; Immunotherapy; 5-fluorouracil; Mice;
D O I
10.3748/wjg.v11.i8.1220
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the effect of CpG-containing oligodeoxynucleotides (CpG ODN) alone or in combination with the chemotherapeutic agent 5-fluorouracil (5-FU) on tumor growth and whether CpG ODN can reverse the immunosuppression caused by the chemotherapy with 5-FU in murine hepatoma model. METHODS: Hepatoma model was established by subcutaneous inoculation with hepatoma-22 (H(22)) cells into the right flank of BALB/c mice. Mice with tumor were treated by peritumoral injection of CpG ODN alone or in combination with subcutaneous injection of 5-FU. Tumor size was quantified regularly. Serum levels of IL-12 and IFN-gamma in mice were assayed by enzyme-linked immunosorbent assay (ELISA). The lytic capacity of splenic NK cells was tested by lactate dehydrogenase release assay. RESULTS: Peritumoral injection of CpG ODN alone or in combination with subcutaneous injection of 5-FU, and the treatment with 5-FU alone all led to significant inhibition of hepatoma growth. The mean tumor volumes fell by 46.66% in mice injected with CpG ODN, 68.34% in the 5-FU treated mice, and 70.23% in mice treated with the combination of CpG ODN and 5-FU than in controls. There was no significant difference in tumor size between 5-FU-treated mice and mice treated with the combination of 5-FU and CpG ODN (P>0.05). The serum levels of IL-12 and IFN-gamma of mice treated with CpG ODN alone (IL-12: 464.50 +/- 24.37 pg/mL; IFN-gamma: 134.20 +/- 25.76 pg/mL) or with the co-administration of CpG ODN and 5-FU (IL-12: 335.83 +/- 28.74 pg/mL; IFN-gamma: 111.00 +/- 5.33 pg/mL) were significantly higher than that of controls (IL-12: 237.50 +/- 45.31 pg/mL; IFN-gamma: 56.75 +/- 8.22 pg/mL). The production of IL-12 and IFN-gamma was suppressed moderately in 5-FU-treated mice (IL-12: 166.67 +/- 53.22 pg/mL; 53.33 +/- 16.98 pg/mL) compared to control mice (P>0.05), whereas the combination of CpG ODN and 5-FU significantly increased the serum levels of IL-12 and IFN-gamma compared to 5-FU alone (P<0.05). The NK cell killing activity in CpG ODN-treated mice (44.04 +/- 1.38%) or the mice treated with CpG ODN combined with 5-FU (30.67 +/- 1.28%) was significantly potentiated compared to controls (19.22 +/- 0.95%, P<0.05). The co-administration of CpG ODN and 5-FU also significantly enhanced the lytic activity of NK cells when compared with the treatment with 5-FU alone (12.03 +/- 1.42%, P<0.05). CONCLUSION: The present data suggests that CpG ODN used as single therapeutic agent triggers anti-tumor immune response to inhibit the growth of implanted hepatoma and reverses the immunosuppression caused by the chemotherapy with 5-FU. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:1220 / 1224
页数:5
相关论文
共 25 条
[1]  
Baines J, 2003, CLIN CANCER RES, V9, P2693
[2]   Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs [J].
Ballas, ZK ;
Krieg, AM ;
Warren, T ;
Rasmussen, W ;
Davis, HL ;
Waldschmidt, M ;
Weiner, GJ .
JOURNAL OF IMMUNOLOGY, 2001, 167 (09) :4878-4886
[3]  
Ballas ZK, 1996, J IMMUNOL, V157, P1840
[4]   Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients [J].
Blazar, BR ;
Krieg, AM ;
Taylor, PA .
BLOOD, 2001, 98 (04) :1217-1225
[5]  
Carpentier AF, 2000, CLIN CANCER RES, V6, P2469
[6]  
Carpentier AF, 1999, CANCER RES, V59, P5429
[7]   Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 [J].
Chace, JH ;
Hooker, NA ;
Mildenstein, KL ;
Krieg, AM ;
Cowdery, JS .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 84 (02) :185-193
[8]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[9]   Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity [J].
Davila, E ;
Celis, E .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :539-547
[10]   Interleukin-12-and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice [J].
Gramzinski, RA ;
Doolan, DL ;
Sedegah, M ;
Davis, HL ;
Krieg, AM ;
Hoffman, SL .
INFECTION AND IMMUNITY, 2001, 69 (03) :1643-1649